Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Governance Documents Committees Year None202420232022 May 9, 2024 Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments April 22, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares April 18, 2024 Biohaven Announces Pricing of $230 Million Public Offering of Common Shares April 17, 2024 Biohaven Announces Proposed Public Offering of Common Shares April 13, 2024 Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates February 29, 2024 Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments January 8, 2024 Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology January 2, 2024 Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Data Provided by Refinitiv. Minimum 15 minutes delayed.
Year None202420232022 May 9, 2024 Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments April 22, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares April 18, 2024 Biohaven Announces Pricing of $230 Million Public Offering of Common Shares April 17, 2024 Biohaven Announces Proposed Public Offering of Common Shares April 13, 2024 Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates February 29, 2024 Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments January 8, 2024 Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology January 2, 2024 Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
April 22, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
April 13, 2024 Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
February 29, 2024 Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
January 8, 2024 Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology